{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:31Z","timestamp":1792787911403,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.ejim.2009.12.001","type":"journal-article","created":{"date-parts":[[2009,12,30]],"date-time":"2009-12-30T04:29:38Z","timestamp":1262147378000},"page":"70-73","source":"Crossref","is-referenced-by-count":49,"title":["Vaccination, squalene and anti-squalene antibodies: Facts or fiction?"],"prefix":"10.1016","volume":"21","author":[{"given":"Giuseppe","family":"Lippi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Franchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2009.12.001_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10409238309102790","article-title":"Sterol structure and membrane function","volume":"14","author":"Bloch","year":"1983","journal-title":"CRC Crit Rev Biochem"},{"key":"10.1016\/j.ejim.2009.12.001_bib2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/molecules14010540","article-title":"Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology","volume":"14","author":"Huang","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.ejim.2009.12.001_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4161\/hv.4.5.6438","article-title":"Vaccine adjuvants: the dream becomes real","volume":"4","author":"Tagliabue","year":"2008","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.ejim.2009.12.001_bib4","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.vaccine.2008.03.093","article-title":"Safety of MF59 adjuvant","volume":"26","author":"Schultze","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ejim.2009.12.001_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1750-2659.2008.00059.x","article-title":"MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis","volume":"2","author":"Banzhoff","year":"2008","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.ejim.2009.12.001_bib6","doi-asserted-by":"crossref","unstructured":"Dormitzer PR, Rappuoli R, Casini F, et al. Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. PLoS Currents: influenza 2009. Available at http:\/\/knol.google.com\/k\/adjuvant-is-necessary-for-a-robust-immune-response-to-a-single-dose-of-h1n1. Last accessed : 28 November 2009.","DOI":"10.1371\/currents.RRN1025"},{"key":"10.1016\/j.ejim.2009.12.001_bib7","doi-asserted-by":"crossref","unstructured":"Clark TW, Pareek M, Hoschler K, et al. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine \u2014 preliminary report. N Engl J Med 2009 Sep 10, Electronic publication.","DOI":"10.1056\/NEJMoa0907650"},{"key":"10.1016\/j.ejim.2009.12.001_bib8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/INF.0b013e31819d6394","article-title":"Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ejim.2009.12.001_bib9","doi-asserted-by":"crossref","unstructured":"Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med. 2009 Oct 5 (Electronic publication).","DOI":"10.7326\/0000605-200912150-00157"},{"key":"10.1016\/j.ejim.2009.12.001_bib10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ncl.2004.12.011","article-title":"Gulf war syndrome: a toxic exposure? A systematic review","volume":"23","author":"Gronseth","year":"2005","journal-title":"Neurol Clin"},{"key":"10.1016\/j.ejim.2009.12.001_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/exmp.1999.2295","article-title":"Antibodies to squalene in Gulf War syndrome","volume":"68","author":"Asa","year":"2000","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.ejim.2009.12.001_bib12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/exmp.2000.2314","article-title":"Re: antibodies to squalene in Gulf War Syndrome","volume":"68","author":"Alving","year":"2000","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.ejim.2009.12.001_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/exmp.2002.2429","article-title":"Antibodies to squalene in recipients of anthrax vaccine","volume":"73","author":"Asa","year":"2002","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.ejim.2009.12.001_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-1759(00)00268-4","article-title":"Induction and detection of antibodies to squalene","volume":"245","author":"Matyas","year":"2000","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.ejim.2009.12.001_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-1759(02)00180-1","article-title":"Induction and detection of antibodies to squalene. II. Optimization of the assay for murine antibodies","volume":"267","author":"Matyas","year":"2002","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.ejim.2009.12.001_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jim.2003.11.002","article-title":"Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice","volume":"286","author":"Matyas","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.ejim.2009.12.001_bib17","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/CVI.00191-06","article-title":"Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene","volume":"13","author":"Del Giudice","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.ejim.2009.12.001_bib18","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1016\/j.vaccine.2009.03.091","article-title":"Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness","volume":"27","author":"Phillips","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ejim.2009.12.001_bib19","series-title":"Gulf War and Health. Volume 1. Depleted Uranium, Sarin, Pyridostigmine Bromide, Vaccines","year":"2000"},{"key":"10.1016\/j.ejim.2009.12.001_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1749-6632.2002.tb04233.x","article-title":"Immunological responses are not abnormal in symptomatic Gulf War veterans","volume":"966","author":"Everson","year":"2002","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.ejim.2009.12.001_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.biopha.2004.04.009","article-title":"Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine","volume":"58","author":"Kuroda","year":"2004","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ejim.2009.12.001_bib22","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.clpt.6100402","article-title":"MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?","volume":"82","author":"O'Hagan","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2009.12.001_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/14760584.2.2.197","article-title":"MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile","volume":"2","author":"Podda","year":"2003","journal-title":"Expert Rev Vaccines"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620509002441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620509002441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T17:28:14Z","timestamp":1558718894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620509002441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0953620509002441"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2009.12.001","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}